These findings provide real-world clinical evidence supporting the benefit of Chemo+ICI in EGFR-TKI-resistant EGFR-mutant NSCLC, and suggest that LSM may help identify patients most likely to benefit from Chemo+ICI. Here, EGFR is linked to non-small cell lung carcinoma.